Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1986 Mar;51(3):816–825. doi: 10.1128/iai.51.3.816-825.1986

Uveitis induction in the rabbit by muramyl dipeptides.

R V Waters, T G Terrell, G H Jones
PMCID: PMC260971  PMID: 3949381

Abstract

Intraocular inflammation (uveitis) was produced in rabbits by intravenous or subcutaneous treatment with N-acetylmuramyl-L-alanyl-D-isoglutamine and several of its synthetic analogs at doses of greater than or equal to 0.2 mg/kg in saline. A dose-dependent increase in permeability of the ocular blood-aqueous barrier as measured by leakage of protein or fluoresceinated dextran from the serum into the eye was observed from 2 to 14 h after glycopeptide treatment. Peak response occurred at approximately 3 h postdose. The lowest dose found to produce maximal vascular leakage for the most active glycopeptide analogs was 1 mg/kg. The adjuvant-inactive L-L stereoisomer of N-acetylmuramyl-L-alanyl-D-isoglutamine was inactive, even at doses as high as 10 mg/kg. Analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine which were homologous in the lactyl side chain were found to cause less uveitis. Chronic biweekly intravenous treatment of rabbits for 1 month with either N-acetyl-L-alpha-aminobutyryl-D-isoglutamine or its lipophilic 6-O-stearoyl derivative at 1 mg/kg, but not with murabutide, resulted in leukocytic inflammatory lesions unique to the uveal tract of the eye. The uveitis was potentially reversible and occurred with decreased severity as long as 2 months after cessation of chronic treatment. Vascular leakage but not cellular infiltrate in the choroid could be modulated by pharmacologic means. Pyrogenicity but not adjuvanticity correlated with ability of glycopeptides to induce vascular leakage. Several adjuvant-active muramyl dipeptide analogs with minimal ability to cause acute vascular leakage or chronic inflammation in the rabbit eye have been identified.

Full text

PDF
816

Images in this article

821Image
on p.821
822Image
on p.822

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Audibert F. M., Przewlocki G., Leclerc C. D., Jolivet M. E., Gras-Masse H. S., Tartar A. L., Chedid L. A. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens. Infect Immun. 1984 Jul;45(1):261–266. doi: 10.1128/iai.45.1.261-266.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azuma I., Kamisango K. I., Saiki I., Tanio Y., Kobayashi S., Yamamura Y. Adjuvant activity of N-acetyl muramyl dipeptides for the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs. Infect Immun. 1980 Sep;29(3):1193–1196. doi: 10.1128/iai.29.3.1193-1196.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhattacherjee P., Hammond B., Salmon J. A., Stepney R., Eakins K. E. Chemotactic response to some arachidonic acid lipoxygenase products in the rabbit eye. Eur J Pharmacol. 1981 Jul 17;73(1):21–28. doi: 10.1016/0014-2999(81)90141-2. [DOI] [PubMed] [Google Scholar]
  4. Bhattacherjee P. Release of prostaglandin-like substances by Shigella endotoxin and its inhibition by non-steroidal anti-inflammatory compounds. Br J Pharmacol. 1975 Aug;54(4):489–494. doi: 10.1111/j.1476-5381.1975.tb07595.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhattacherjee P., Williams R. N., Eakins K. E. A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. Invest Ophthalmol Vis Sci. 1983 Aug;24(8):1143–1146. [PubMed] [Google Scholar]
  6. Bhattacherjee P., Williams R. N., Eakins K. E. An evaluation of ocular inflammation following the injection of bacterial endotoxin into the rat foot pad. Invest Ophthalmol Vis Sci. 1983 Feb;24(2):196–202. [PubMed] [Google Scholar]
  7. Bito L. Z. The effects of experimental uveitis on anterior uveal prostaglandin transport and aqueous humor composition. Invest Ophthalmol. 1974 Dec;13(12):959–966. [PubMed] [Google Scholar]
  8. Byars N. E. Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs. Infect Immun. 1984 May;44(2):344–350. doi: 10.1128/iai.44.2.344-350.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Calin A., Fries J. F. An "experimental" epidemic of Reiter's syndrome revisited. Follow-up evidence on genetic and environmental factors. Ann Intern Med. 1976 May;84(5):564–566. doi: 10.7326/0003-4819-84-5-564. [DOI] [PubMed] [Google Scholar]
  10. Chedid L. A., Parant M. A., Audibert F. M., Riveau G. J., Parant F. J., Lederer E., Choay J. P., Lefrancier P. L. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun. 1982 Feb;35(2):417–424. doi: 10.1128/iai.35.2.417-424.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cousins S. W., Guss R. B., Howes E. L., Jr, Rosenbaum J. T. Endotoxin-induced uveitis in the rat: observations on altered vascular permeability, clinical findings, and histology. Exp Eye Res. 1984 Nov;39(5):665–676. doi: 10.1016/0014-4835(84)90065-4. [DOI] [PubMed] [Google Scholar]
  12. Cummings N. P., Pabst M. J., Johnston R. B., Jr Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J Exp Med. 1980 Dec 1;152(6):1659–1669. doi: 10.1084/jem.152.6.1659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Defreyn G., Deckmyn H., Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res. 1982 Jun 15;26(6):389–400. doi: 10.1016/0049-3848(82)90311-5. [DOI] [PubMed] [Google Scholar]
  14. Eakins K. E. Prostaglandin and non-prostaglandin mediated breeakdown of the blood-aqueous barrier. Exp Eye Res. 1977;25 (Suppl):483–498. doi: 10.1016/s0014-4835(77)80043-2. [DOI] [PubMed] [Google Scholar]
  15. Egan R. W., Tischler A. N., Baptista E. M., Ham E. A., Soderman D. D., Gale P. H. Specific inhibition and oxidative regulation of 5-lipoxygenase. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:151–157. [PubMed] [Google Scholar]
  16. Floman N., Zor U. Mechanism of steroid action in ocular inflammation: Inhibition of prostaglandin production. Invest Ophthalmol Vis Sci. 1977 Jan;16(1):69–73. [PubMed] [Google Scholar]
  17. Fox A., Hammer M. E., Lill P., Burch T. G., Burrish G. Experimental uveitis. Elicited by peptidoglycan-polysaccharide complexes, lipopolysaccharide, and muramyl dipeptide. Arch Ophthalmol. 1984 Jul;102(7):1063–1067. doi: 10.1001/archopht.1984.01040030857033. [DOI] [PubMed] [Google Scholar]
  18. Fraser-Smith E. B., Matthews T. R. Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice. Infect Immun. 1981 Dec;34(3):676–683. doi: 10.1128/iai.34.3.676-683.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fraser-Smith E. B., Waters R. V., Matthews T. R. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Infect Immun. 1982 Jan;35(1):105–110. doi: 10.1128/iai.35.1.105-110.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Gamble C. N., Aronson S. B., Brescia F. B. Experimental uveitis. I. The production of recurrent immunologic (Auer) uveitis and its relationship to increased uveal vascular permeability. Arch Ophthalmol. 1970 Sep;84(3):321–330. doi: 10.1001/archopht.1970.00990040323012. [DOI] [PubMed] [Google Scholar]
  21. Howes E. L., Jr, Aronson S. B., McKay D. G. Ocular vascular permeability. Effect of systemic administration of bacterial endotoxin. Arch Ophthalmol. 1970 Sep;84(3):360–367. doi: 10.1001/archopht.1970.00990040362017. [DOI] [PubMed] [Google Scholar]
  22. Howes E. L., Jr, Goldyne M. E., Perez H. D., Goldstein I. M., Rosenbaum J. T. Lipopolysaccharide tolerance inhibits eye inflammation. I. Reduced immune complex or lipopolysaccharide effects. Arch Ophthalmol. 1985 Feb;103(2):257–260. doi: 10.1001/archopht.1985.01050020109031. [DOI] [PubMed] [Google Scholar]
  23. Howes E. L., Jr, McKay D. G., Margaretten W. The participation of the platelet in the vascular response to endotoxemia in the rabbit eye. Am J Pathol. 1973 Jan;70(1):25–44. [PMC free article] [PubMed] [Google Scholar]
  24. Howes E. L., Jr, Wong K. L., Hartiala K. T., Webster R. O., Rosenbaum J. T. Complement and polymorphonuclear leukocytes do not determine the vascular permeability induced by intraocular LPS. Am J Pathol. 1985 Jan;118(1):35–42. [PMC free article] [PubMed] [Google Scholar]
  25. Hultsch E. Peripheral uveitis in the owl monkey. Experimental model. Mod Probl Ophthalmol. 1977;18:247–251. [PubMed] [Google Scholar]
  26. Kadlec O., Masek K., Gulda O., Růzicka V., Parant M., Chedid L. Smooth muscle stimulation by an immunomodulatory compound muramyl dipeptide: does it involve serotoninergic system? Pharmacology. 1984;29(1):31–39. doi: 10.1159/000137989. [DOI] [PubMed] [Google Scholar]
  27. Kireszenbaum F., Ferraresi R. W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kotani S., Watanabe Y., Shimono T., Harada K., Shiba T. Correlation between the immunoadjuvant activities and pyrogenicities of synthetic N-acetylmuramyl-peptides or -amino acids. Biken J. 1976 Mar;19(1):9–13. [PubMed] [Google Scholar]
  29. Krahenbuhl J. L., Sharma S. D., Ferraresi R. W., Remington J. S. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice. Infect Immun. 1981 Feb;31(2):716–722. doi: 10.1128/iai.31.2.716-722.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Mathews W. R., Murphy R. C. Inhibition of leukotriene biosynthesis in mastocytoma cells by diethylcarbamazine. Biochem Pharmacol. 1982 Jun 1;31(11):2129–2132. doi: 10.1016/0006-2952(82)90435-x. [DOI] [PubMed] [Google Scholar]
  31. Matsumoto K., Ogawa H., Kusama T., Nagase O., Sawaki N., Inage M., Kusumoto S., Shiba T., Azuma I. Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice. Infect Immun. 1981 May;32(2):748–758. doi: 10.1128/iai.32.2.748-758.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Morozumi P. A., Brummer E., Stevens D. A. Immunostimulation with muramyl dipeptide and its desmethyl analogue: Studies of non-specific resistance to pulmonary blastomycosis in inbred mouse strains. Mycopathologia. 1983 Jan 17;81(1):35–39. doi: 10.1007/BF00443907. [DOI] [PubMed] [Google Scholar]
  33. Osada Y., Otani T., Sato M., Une T., Matsumoto K., Ogawa H. Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog. Infect Immun. 1982 Dec;38(3):848–854. doi: 10.1128/iai.38.3.848-854.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Roch-Arveiller M., Tissot M., Moachon L., Giroud J. P. Effect of immunomodulating agents on leucocyte chemotaxis and cyclic nucleotides. Agents Actions. 1982 Jul;12(3):353–359. doi: 10.1007/BF01965403. [DOI] [PubMed] [Google Scholar]
  35. Rogers J. D. Biopharmaceutical evaluation of 'Osmosin'. Curr Med Res Opin. 1983;8 (Suppl 2):38–54. doi: 10.1185/03007998309109822. [DOI] [PubMed] [Google Scholar]
  36. Rosenbaum J. T., McDevitt H. O., Guss R. B., Egbert P. R. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980 Aug 7;286(5773):611–613. doi: 10.1038/286611a0. [DOI] [PubMed] [Google Scholar]
  37. Rylatt D. B., Parish C. R. Protein determination on an automatic spectrophotometer. Anal Biochem. 1982 Mar 15;121(1):213–214. doi: 10.1016/0003-2697(82)90578-4. [DOI] [PubMed] [Google Scholar]
  38. Silverman D. H., Wu H., Karnovsky M. L. Muramyl peptides and serotonin interact at specific binding sites on macrophages and enhance superoxide release. Biochem Biophys Res Commun. 1985 Sep 30;131(3):1160–1167. doi: 10.1016/0006-291x(85)90212-8. [DOI] [PubMed] [Google Scholar]
  39. Wahl S. M., Wahl L. M., McCarthy J. B., Chedid L., Mergenhagen S. E. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979 Jun;122(6):2226–2231. [PubMed] [Google Scholar]
  40. Williams R. N., Bhattacherjee P., Eakins K. E. Biosynthesis of lipoxygenase products by ocular tissues. Exp Eye Res. 1983 Mar;36(3):397–402. doi: 10.1016/0014-4835(83)90121-5. [DOI] [PubMed] [Google Scholar]
  41. Zídek Z., Maśek K., Jiricka Z. Arthritogenic activity of a synthetic immunoadjuvant, muramyl dipeptide. Infect Immun. 1982 Feb;35(2):674–679. doi: 10.1128/iai.35.2.674-679.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. den Ottolander G. J., te Velde J., Veenhof W., Kleiverda K., Haak H. L., Spaander P. J. Busulphan aplasia in rabbits: a model for human aplastic anaemia. Br J Haematol. 1982 Jun;51(2):265–276. doi: 10.1111/j.1365-2141.1982.tb02780.x. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES